Valerie Quach

Valerie Quach

Auto-generated profile, based on publicly available information

Valerie Quach

John Sealy School of Medicine, University of Texas Medical Branch, Galveston, Texas

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2026 in The American Journal of Cardiology
Verified
Journal Article
Closed access
IMIbrahim Mortada
Ibrahim Mortada
ALAaron Lee
Aaron Lee
ASAyushi Sahu
Ayushi Sahu
CNCullins Nwaogu
Cullins Nwaogu
VQValerie Quach
Valerie Quach
HJHani Jneid
Hani Jneid

19 March 2026 in The American Journal of Cardiology
Verified
Journal Article
Closed access
IMIbrahim Mortada
Ibrahim Mortada
ALAaron Lee
Aaron Lee
VQValerie Quach
Valerie Quach
JRJames Rice
James Rice
SMShareef Mansour
Shareef Mansour
HJHani Jneid
Hani Jneid

23 April 2026 in Journal of the Society for Cardiovascular Angiography & Interventions
Verified
Journal Article
Open access
IMIbrahim Mortada
Ibrahim Mortada
VQValerie Quach
Valerie Quach
ALAaron Lee
Aaron Lee
NLNicholas Long
Nicholas Long
GEGrant Ebel
Grant Ebel
HJHani Jneid
Hani Jneid

17 August 2026 in Therapeutic Advances in Cardiovascular Disease
Verified
Journal Article
Open access
IMIbrahim Mortada
Ibrahim Mortada
ALAaron Lee
Aaron Lee
DBDalton Buckingham
Dalton Buckingham
VQValerie Quach
Valerie Quach
JRJames Rice
James Rice
HJHani Jneid
Hani Jneid
Background: Sex-related differences are well recognized in heart failure with preserved ejection fraction (HFpEF), but real-world data describing clinical outcomes by sex among patients with obesity and HFpEF treated with tirzepatide remain limited. Objectives: To compare observed hospitalization, cardiovascular, and gastrointestinal outcomes between male and female patients with obesity and HFpEF treated with tirzepatide. Design: Retrospective, propensity score-matched, within-treatment cohort study. Methods: A retrospective study was conducted using TriNetX database which included 110 healthcare organizations. Adults with obesity, HFpEF, and taking tirzepatide between June 1, 2022 and January 1, 2025 were identified. Males and females were balanced using 1:1 propensity score matching (n=1,654 per group). Primary outcome assessed included all-cause hospitalization. Secondary outcomes were all-cause mortality, HF exacerbation, major adverse cardiovascular events (MACE), incident atrial fibrillation, nausea/vomiting and diarrhea. Two prespecified falsification endpoints were used. Results: During 1-year follow-up, males had a lower hazard of all-cause hospitalization compared with females (HR 0.87, 95% CI 0.77–0.98). No significant differences were observed for all-cause mortality (HR 1.73, 95% CI 0.95–3.18), HF exacerbation (HR 1.14, 95% CI 0.90–1.44), MACE (HR 1.28, 95% CI 0.99–1.65), or incident atrial fibrillation (HR 1.21, 95% CI 0.61–2.43). Males experienced lower rates of nausea and vomiting (HR 0.50, 95% CI 0.37–0.67), while diarrhea was similar (HR 0.84, 95% CI 0.59–1.19). Falsification endpoints showed no significant associations. Conclusion: Among tirzepatide-treated patients with obesity and HFpEF, no statistically significant sex-associated differences were detected in major cardiovascular outcomes. Males had a modestly lower observed hazard of hospitalization and fewer coded nausea and vomiting events. Because this was a within-treatment observational comparison without an external comparator, these findings should not be interpreted as evidence of differential tirzepatide effectiveness by sex.